Download Files:
UCM-1306
$150 – $1,250
Products Details
Product Description
– UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD)[1].
Web ID
– HY-148867
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C14H14FNO2S
References
– [1]GarcÃa-Cárceles J, et, al. 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson’s Disease. J Med Chem. 2022 Sep 22;65(18):12256-12272.
CAS Number
– 2258608-78-3
Molecular Weight
– 279.33
Compound Purity
– 99.61
SMILES
– O=S(C1=CC=C(C2=C(OCF)C=CC=C2)C=C1)(C)=N
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– Dopamine Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
